type I diabetes

[NPJ Regenerative Medicine] In the type 1 diabetic NOD mouse model, engineered growth factors improved both re-epithelialization and granulation tissue formation.

[CRISPR Therapeutics, Inc.] CRISPR Therapeutics,Inc. and ViaCyte, Inc., announced that Health Canada has approved the companies’ Clinical Trial Application for VCTX210, an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes. Initiation of patient enrollment is expected by year-end.

[Diabetes Research Connection (Business Wire, Inc.)] Diabetes Research Connection has provided funds were provided to seven researchers totaling a $400,000 investment aimed at prevention, cure, and better care for those with Type 1 Diabetes .

[Frontiers in Endocrinology] The authors differentiated iPSC from one donor into dendritic cells, macrophages, endothelial cells, and β-cells, and engineered T cell avatars from the same donor to provide an in vitro platform to study genetic influences on critical cellular interactions.

[SymbioCellTech (GlobeNewswire, Inc.)] SymbioCellTech announced the publication of a paper demonstrating the potency and efficacy of its innovative and proprietary human Neo-Islet™ in a third, clinically relevant model of human Type 1 Diabetes.

[Provention Bio, Inc.] Provention Bio, Inc. announced positive interim results from PROVENT, a first-in-human study of PRV-101, a polyvalent inactivated coxsackievirus B vaccine candidate targeting all five key CVB strains associated with type 1 diabetes autoimmunity.